The only company targeting tumor hypoxia (atleast public) is THLD - who actually are using their TH-302 in combo with a few different chemos. Not sure if any are antiangiogenic agents though. I know they are doing trials with TH-302 + doxorubicin (phase 3) and TH-302 + gemcitabine (pancreatic cancer phase 2) I believe there also is a phase 2 with TH-302 and pemetrexed (solid tumors - phase 1/2)
They have a few phase 1s with sunitinib and bevacizumab - and some planned with TH-302 + bortezomib, pazopanib and sorafinib. I guess these are VEGFR anti-angiogenic drugs
Market Data 
Markets 
AI
